FEMY vs BDX vs HOLX vs BAX vs SYK

For growth investors, Femasys Inc.

(FEMY) is the stronger pick with 40. 8% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.

3x versus Stryker Corporation at 35. 0x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus Stryker Corporation's 1. 28x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -96. 3% for Femasys Inc. (FEMY). Over 10 years, the gap is even starker: SYK returned +179. 2% versus FEMY's -96. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus Baxter International Inc. 's 1. 38β — meaning BAX is approximately 205% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Femasys Inc.

(FEMY) is pulling ahead at 40. 8% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Femasys Inc. grew EPS 44. 0% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, FEMY leads at 23. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -812. 3% for Femasys Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -767. 0% for FEMY. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus Stryker Corporation's 1. 28x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 4x forward P/E versus 19. 1x for Stryker Corporation — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SYK: 32. 4% to $389. 62.

In this comparison, BAX (3.

9% yield), BDX (2. 7% yield), SYK (1. 1% yield) pay a dividend. FEMY, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 1% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, FEMY: -96. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FEMY is a small-cap high-growth stock; BDX is a mid-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock; SYK is a mid-cap quality compounder stock. BDX, BAX, SYK pay a dividend while FEMY, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.